% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kanwar:867577,
author = {Kanwar, Rohini and Gradzielski, Michael and Prevost,
Sylvain and Appavou, Marie-Sousai and Mehta, S. K.},
title = {{E}xperimental validation of biocompatible nanostructured
lipid carriers of sophorolipid: {O}ptimization,
characterization and in-vitro evaluation},
journal = {Colloids and surfaces / B Biointerfaces B},
volume = {181},
issn = {0927-7765},
address = {[S.l.]},
publisher = {Science Direct},
reportid = {FZJ-2019-06200},
pages = {845 - 855},
year = {2019},
abstract = {To date, the potential of sophorolipids (an important class
of glycolipids) has been exploited solely as amphipathic
molecules but their ability to formulate lipid nanoparticles
has never been explored. In this report, for the first time,
lipid nanostructures coated with polysorbates (Tweens) were
formulated by a hot dispersion method. By varying the amount
of lipid, type of surfactant, and alcohol, dilution ratio
etc., the formulation was optimized with respect to its
stability, which is a central aspect of their potential
applications. Their comprehensive physicochemical
characterization was done using static and dynamic light
scattering (SLS, DLS), small angle neutron scattering
(SANS), zeta-potential, transmission electron microscopy
(TEM), scanning electron microscopy (SEM), and atomic force
microscopy (AFM) techniques. Further hemolysis study was
conducted to understand the in-vitro cytotoxicity levels of
the lipidic nanoparticles prior to its application as a
potent drug delivery device for countermanding the problems
associated with challenging tuberculosis and leprosy
drug-Rifampicin. Attaining high entrapment efficiency and
sustained release from the developed carrier, further
interaction with bovine serum albumin was investigated, to
understand the in-vivo behavior of the nanostructured lipid
carriers (NLCs).},
cin = {JCNS-FRM-II / JCNS-1 / MLZ},
ddc = {540},
cid = {I:(DE-Juel1)JCNS-FRM-II-20110218 /
I:(DE-Juel1)JCNS-1-20110106 / I:(DE-588b)4597118-3},
pnm = {6G4 - Jülich Centre for Neutron Research (JCNS) (POF3-623)
/ 6G15 - FRM II / MLZ (POF3-6G15)},
pid = {G:(DE-HGF)POF3-6G4 / G:(DE-HGF)POF3-6G15},
experiment = {EXP:(DE-MLZ)KWS1-20140101},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31254745},
UT = {WOS:000481565300098},
doi = {10.1016/j.colsurfb.2019.06.036},
url = {https://juser.fz-juelich.de/record/867577},
}